Advertisement

Neuroscience Bulletin

, Volume 35, Issue 1, pp 15–24 | Cite as

Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway

  • Jian Guan
  • Miao Zhao
  • Chao He
  • Xue Li
  • Ying Li
  • Jie Sun
  • Wei Wang
  • Ya-Li Cui
  • Qing Zhang
  • Bai-Yan LiEmail author
  • Guo-Fen QiaoEmail author
Original Article
  • 124 Downloads

Abstract

Fenofibrate, an agonist for peroxisome proliferator-activated receptor alpha (PPAR-α), lowers blood pressure, but whether this action is mediated via baroreflex afferents has not been elucidated. In this study, the distribution of PPAR-α and PPAR-γ was assessed in the nodose ganglion (NG) and the nucleus of the solitary tract (NTS). Hypertension induced by drinking high fructose (HFD) was reduced, along with complete restoration of impaired baroreceptor sensitivity, by chronic treatment with fenofibrate. The molecular data also showed that both PPAR-α and PPAR-γ were dramatically up-regulated in the NG and NTS of the HFD group. Expression of the downstream signaling molecule of PPAR-α, the mitochondrial uncoupling protein 2 (UCP2), was up-regulated in the baroreflex afferent pathway under similar experimental conditions, along with amelioration of reduced superoxide dismutase activity and increased superoxide in HFD rats. These results suggest that chronic treatment with fenofibrate plays a crucial role in the neural control of blood pressure by improving baroreflex afferent function due at least partially to PPAR-mediated up-regulation of UCP2 expression and reduction of oxidative stress.

Keywords

Fenofibrate Peroxisome proliferator-activated receptor Mitochondrial uncoupling protein Baroreflex afferent function Blood pressure regulation 

Notes

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81573431 and 81773731).

Compliance with Ethical Standards

Conflict of interest

These authors declare no conflict of interest.

Supplementary material

12264_2018_271_MOESM1_ESM.pdf (63 kb)
Supplementary material 1 (PDF 62 kb)

References

  1. 1.
    Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000, 405: 421–424.Google Scholar
  2. 2.
    Lu KL, Xu WN, Li XF, Liu WB, Wang LN, Zhang CN. Hepatic triacylglycerol secretion, lipid transport and tissue lipid uptake in blunt snout bream (Megalobrama amblycephala) fed high-fat diet. Aquaculture 2013, 408–409: 160–168.Google Scholar
  3. 3.
    Vikramadithyan RK, Hirata K, Yagyu H, Hu Y, Augustus A, Homma S, et al. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther 2005, 313: 586–593.Google Scholar
  4. 4.
    Rani N, Bharti S, Bhatia J, Nag TC, Ray R, Arya DS. Chrysin, a PPAR-γ agonist improves myocardial injury in diabetic rats through inhibiting AGE-RAGE mediated oxidative stress and inflammation. Chem Biol Interact 2016, 250: 59–67.Google Scholar
  5. 5.
    Sun K, Park J, Kim M, Scherer PE. Endotrophin, a multifaceted player in metabolic dysregulation and cancer progression, is a predictive biomarker for the response to PPARgamma agonist treatment. Diabetologia 2017, 60: 24–29.Google Scholar
  6. 6.
    Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol 2014, 34: 1298–1306.Google Scholar
  7. 7.
    Petrescu AD, Mcintosh AL, Storey SM, Huang H, Martin GG, Landrock D, et al. High glucose potentiates L-FABP mediated fibrate induction of PPARα in mouse hepatocytes. Biochim Biophys Acta 2013, 1831: 1412–1425.Google Scholar
  8. 8.
    Zhao X, Li LY. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008, 28: 598–606.Google Scholar
  9. 9.
    Yuan X, Tsujimoto K, Hashimoto K, Kawahori K, Hanzawa N, Hamaguchi M, et al. Epigenetic modulation of Fgf21 in the perinatal mouse liver ameliorates diet-induced obesity in adulthood. Nat Commun 2018, 9: 636.Google Scholar
  10. 10.
    He JL, Zhao M, Xia JJ, Guan J, Liu Y, Wang LQ, et al. FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats. Sci Rep 2016, 6: 29582.Google Scholar
  11. 11.
    Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Exp Biol Med 2010, 235: 383–391.Google Scholar
  12. 12.
    Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011, 54: 280–290.Google Scholar
  13. 13.
    Jia Z, Rui X, Liu G, Ling L, Yang J, Pi G, et al. HMGB1 is involved in the protective effect of the PPARα agonist fenofibrate against cardiac hypertrophy. PPAR Res 2014, 2014: 541394.Google Scholar
  14. 14.
    Barbiero JK, Santiago RM, Persike DS, Da SFM, Tonin FS, Da CC, et al. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behav Brain Res 2014, 274: 390–399.Google Scholar
  15. 15.
    Ibarra-Lara L, Cervantes-Pérez LG, Pérez-Severiano F, Valle LD, Rubio-Ruíz E, Soria-Castro E, et al. PPARα stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner. Eur J Pharmacol 2010, 627: 185–193.Google Scholar
  16. 16.
    Tordjman KM, Semenkovich CF, Coleman T, Yudovich R, Bak S, Osher E, et al. Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. Hypertension 2007, 50: 945–951.Google Scholar
  17. 17.
    Ueno H, Saitoh Y, Mizuta M, Shiiya T, Noma K, Mashiba S, et al. Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome. Obes Res Clin Pract 2011, 5: e267–360.Google Scholar
  18. 18.
    Liu Y, Zhou JY, Zhou YH, Wu D, He JL, Han LM, et al. Unique expression of angiotensin type-2 receptor in sex-specific distribution of myelinated Ah-type baroreceptor neuron contributing to sex-dimorphic neurocontrol of circulation. Hypertension 2016, 67: 783–791.Google Scholar
  19. 19.
    Salman IM, Hildreth CM, Ameer OZ, Phillips JK. Differential contribution of afferent and central pathways to the development of baroreflex dysfunction in chronic kidney disease. Hypertension 2014, 63: 804–810.Google Scholar
  20. 20.
    Huber DA, Schreihofer AM. Attenuated baroreflex control of sympathetic nerve activity in obese Zucker rats by central mechanisms. J Physiol 2010, 588: 1515–1525.Google Scholar
  21. 21.
    Kaneko K, Yamada T, Tsukita S, Takahashi K, Ishigaki Y, Oka Y, et al. Obesity alters circadian expressions of molecular clock genes in the brainstem. Brain Res 2009, 1263: 58–68.Google Scholar
  22. 22.
    Borges GR, Morgan DA, Ketsawatsomkron P, Mickle AD, Thompson AP, Cassell MD, et al. Interference with peroxisome proliferator-activated receptor-gamma in vascular smooth muscle causes baroreflex impairment and autonomic dysfunction. Hypertension 2014, 64: 590–596.Google Scholar
  23. 23.
    Chan SH, Wu KL, Kung PS, Chan JY. Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertension 2010, 55: 1444–1453.Google Scholar
  24. 24.
    Braga VA, Colombari E, Jovita MG. Angiotensin II-derived reactive oxygen species underpinning the processing of the cardiovascular reflexes in the medulla oblongata. Neurosci Bull 2011, 27: 269–274.Google Scholar
  25. 25.
    Zhou FM, Cheng RX, Wang S, Huang Y, Gao YJ, Zhou Y, et al. Antioxidants attenuate acute and chronic itch: peripheral and central mechanisms of oxidative stress in pruritus. Neurosci Bull 2017, 33: 1–13.Google Scholar
  26. 26.
    Souza BM, Assmann TS, Kliemann LM, Gross JL, Canani LH, Crispim D. The role of uncoupling protein 2 (UCP2) on the development of type 2 diabetes mellitus and its chronic complications. Arq Bras Endocrinol Metabol 2011, 55: 239–248.Google Scholar
  27. 27.
    Lu M, Zhao FF, Tang JJ, Su CJ, Fan Y, Ding JH, et al. The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive potassium channels. Antioxid Redox Signal 2012, 17: 849–859.Google Scholar
  28. 28.
    Guimaraes PS, Oliveira MF, Braga JF, Nadu AP, Schreihofer A, Santos RA, et al. Increasing angiotensin-(1-7) levels in the brain attenuates metabolic syndrome-related risks in fructose-fed rats. Hypertension 2014, 63: 1078–1085.Google Scholar
  29. 29.
    Tran LT, Yuen VG, Mcneill JH. The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension. Mol Cell Biochem 2009, 332: 145–159.Google Scholar
  30. 30.
    Yu Y, Xue BJ, Wei SG, Zhang ZH, Beltz TG, Guo F, et al. Activation of central PPAR-gamma attenuates angiotensin II-induced hypertension. Hypertension 2015, 66: 403–411.Google Scholar
  31. 31.
    Pierzchala M, Fakhfakh M. Cardioprotective Effect of Combination of Enalapril and Fenofibrate. Lap Lambert Academic Publishing, 2011: 2394–2397.Google Scholar
  32. 32.
    Singh G, Khan MU, Khanam R. Protective role of fibrates in cardiac ischemia/reperfusion. J Adv Pharm Technol Res 2012, 3: 188–192.Google Scholar
  33. 33.
    Arnold AC, Shaltout HA, Gallagher PE, Diz DI. Leptin impairs cardiovagal baroreflex function at the level of the solitary tract nucleus. Hypertension 2009, 54: 1001–1008.Google Scholar
  34. 34.
    Zhang D, Liu J, Tu H, Muelleman RL, Cornish KG, Li YL. In-vivo transfection of manganese superoxide dismutase gene or NFκB shRNA in nodose ganglia improves aortic baroreceptor function in heart failure rats. Hypertension 2014, 63: 88.Google Scholar
  35. 35.
    Qiao GF, Li BY, Lu YJ, Fu YL, Schild JH. 17Beta-estradiol restores excitability of a sexually dimorphic subset of myelinated vagal afferents in ovariectomized rats. Am J Physiol Cell Physiol 2009, 297: C654–C664.Google Scholar
  36. 36.
    Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3: 1101.Google Scholar
  37. 37.
    Li JN, Li XL, He J, Wang JX, Zhao M, Liang XB, et al. Sex- and afferent-specific differences in histamine receptor expression in vagal afferents of rats: A potential mechanism for sexual dimorphism in prevalence and severity of asthma. Neuroscience 2015, 303: 166–177.Google Scholar
  38. 38.
    Kaimoto S, Hoshino A, Ariyoshi M, Okawa Y, Tateishi S, Ono K, et al. Activation of PPARα in the early stage of heart failure maintained myocardial function and energetics in pressure overload heart failure. Am J Physiol Heart Circ Physiol 2016, 312: H305–H313.Google Scholar
  39. 39.
    Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, et al. Rescue of cardiomyopathy in PPARα transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and PPARα activators. Circulation 2010, 121: 426–435.Google Scholar
  40. 40.
    Evans LC, Ivy JR, Caitlin W, Mcnairn JA, Menzies RI, Christensen TH, et al. Conditional deletion of Hsd11b2in the brain causes salt appetite and hypertension. Circulation 2016, 133: 1360–1370.Google Scholar
  41. 41.
    Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, et al. Effects of electrical stimulation of carotid baroreflex and renal denervation on atrial electrophysiology. J Cardiovasc Electrophysiol 2013, 24: 1028–1033.Google Scholar
  42. 42.
    Bukhari IA, Almotrefi AA, Mohamed OY, Masri AAA. Fenofibrate inhibits ischemia-reperfusion induced cardiac arrhythmias in isolated rat hearts. FASEB J 2013, 27: 652.Google Scholar
  43. 43.
    Ruby MA, Goldenson B, Orasanu G, Johnston TP, Plutzky J, Krauss RM. VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids. J Lipid Res 2010, 51: 2275–2281.Google Scholar
  44. 44.
    Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med 2013, 19: 1252–1263.Google Scholar
  45. 45.
    Nam JS, Chung HJ, Jang MK, Jung IA, Park SH, Cho SI, et al. Sasa borealis extract exerts an antidiabetic effect via activation of the AMP-activated protein kinase. Nutr Res Pract 2013, 7: 15–21.Google Scholar
  46. 46.
    Pons DG, Nadal-Serrano M, Torrens-Mas M, Valle A, Oliver J, Roca P. UCP2 inhibition sensitizes breast cancer cells to therapeutic agents by increasing oxidative stress. Free Radic Biol Med 2015, 86: 67–77.Google Scholar
  47. 47.
    Cardoso S, Santos MS, Moreno A, Moreira PI. UCP2 and ANT differently modulate proton-leak in brain mitochondria of long-term hyperglycemic and recurrent hypoglycemic rats. J Bioenerg Biomembr 2013, 45: 397–407.Google Scholar
  48. 48.
    Diano S, Horvath TL. Mitochondrial uncoupling protein 2 (UCP2) in glucose and lipid metabolism. Trends Mol Med 2012, 18: 52–58.Google Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Jian Guan
    • 1
  • Miao Zhao
    • 1
  • Chao He
    • 1
  • Xue Li
    • 1
  • Ying Li
    • 1
  • Jie Sun
    • 1
  • Wei Wang
    • 1
  • Ya-Li Cui
    • 1
  • Qing Zhang
    • 1
  • Bai-Yan Li
    • 1
    Email author
  • Guo-Fen Qiao
    • 1
    Email author
  1. 1.Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of PharmacyHarbin Medical UniversityHarbinChina

Personalised recommendations